REG - Verici Dx PLC - Publication of Circular

Verici DxAnnouncement

Yesterday 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250509:nRSI1422Ia&default-theme=true

RNS Number : 1422I  Verici Dx PLC  09 May 2025

 

 

 

Verici Dx plc

("Verici" or the "Company")

 

Publication of Circular

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that a Circular, containing a notice of general
meeting, has been published today seeking Shareholder approval to issue and
allot new Ordinary Shares on a non-pre-emptive basis at a general meeting due
to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M
9DQ at 11:30 a.m. on 27 May 2025 ("General Meeting").

 

Following the announcement on 7 April 2025, the Company is proposing to carry
out a Fundraising (the "Fundraising") to raise funds to enable it, inter alia,
to accelerate commercial growth and support the scale up of Tutivia™
revenues. The Fundraising is required to extend the cash runway and enable the
Company to achieve its commercial objectives having now secured Medicare
Coverage for Tutivia™ as announced on 10 April 2025.

 

The existing allotment authorities the Company has from its last annual
general meeting are anticipated to be insufficient for the proposed
Fundraising and accordingly, the Company is proposing to obtain sufficient
further authority to issue and allot new Ordinary Shares on a non-pre-emptive
basis at the General Meeting.

 

The size and structure of the Fundraising is yet to be determined by the
Board, however it is anticipated to include a placing with institutional and
other investors. The Company, in consultation with its advisers, will
determine the appropriate size, structure and timing of the Fundraising in due
course and a further update will be provided by the Company as and when deemed
appropriate.

 

The Circular and notices of availability of the Circular on the Company's
website will be posted to Shareholders today and these documents will also be
available later today on the Company's website at:

 

https://vericidx.com/investors/documents/
(https://vericidx.com/investors/documents/)

 

Unless otherwise defined, all definitions used in this announcement will have
the same meaning as described in the Circular.

 

Enquiries:

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)
 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)                         Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
                                               (mailto:vericidx@walbrookpr.com)
 Paul McManus                                  Mob: +44 (0)7980 541 893

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

 

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBUGDURXGDGUC